These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 5031613)

  • 21. Changes in liver lysosome fragility, erythrocyte membrane stability, and local and systemic lysosomal enzyme levels in adjuvant-induced polyarthritis.
    Ignarro LJ; Slywka J
    Biochem Pharmacol; 1972 Mar; 21(6):875-86. PubMed ID: 4622578
    [No Abstract]   [Full Text] [Related]  

  • 22. [Biochemistry of immunologic adjuvant effect of Mycobacterial cell wall].
    Kotani S
    Kekkaku; 1975 Dec; 50(11):455-60. PubMed ID: 1221148
    [No Abstract]   [Full Text] [Related]  

  • 23. [Adjuvant activity of peptidoglyoans from mycobacteria].
    Adam A; Amar C; Ciorbaru R; Lederer E; Petit JF; Vilkas E
    C R Acad Hebd Seances Acad Sci D; 1974 Feb; 278(6):799-801. PubMed ID: 4211289
    [No Abstract]   [Full Text] [Related]  

  • 24. CHEMOTHERAPY OF ARTHRITIS INDUCED IN RATS BY MYCOBACTERIAL ADJUVANT.
    NEWBOULD BB
    Br J Pharmacol Chemother; 1963 Aug; 21(1):127-36. PubMed ID: 14066137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of previous subliminal doses of mycobacterial adjuvant on adjuvant disease].
    Houssay RH; Eugui EM
    Medicina (B Aires); 1971; 31(4):281-8. PubMed ID: 4942876
    [No Abstract]   [Full Text] [Related]  

  • 26. Adjuvants and the reticuloendothelial system. The recall phenomenon of the stimulatory effects of adjuvants with homologous antigen.
    Aiyedun BA
    J Reticuloendothel Soc; 1972 Dec; 12(6):672-700. PubMed ID: 4197668
    [No Abstract]   [Full Text] [Related]  

  • 27. Peptidoglycan adjuvants: minimal structure required for activity.
    Adam A; Ellouz F; Ciorbaru R; Petit JF; Lederer E
    Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(2-4):341-8. PubMed ID: 126566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparability of adjuvant disease of rats with human diseases].
    Schmidt K; Ott VR
    Schweiz Med Wochenschr; 1973 Aug; 103(31):1099-103. PubMed ID: 4796194
    [No Abstract]   [Full Text] [Related]  

  • 29. Adjuvant experimental polyarthritis.
    Zahiri H; Gagnon J; Ayotte R; Laurin CA
    Can Med Assoc J; 1969 Sep; 101(5):269-78. PubMed ID: 5812110
    [No Abstract]   [Full Text] [Related]  

  • 30. IMMUNOLOGIC UNRESPONSIVENESS IN THE ADULT GUINEA PIG. I. SUPPRESSION OF DELAYED HYPERSENSITIVITY AND ANTIBODY FORMATION TO PROTEIN ANTIGENS.
    DVORAK HF; BILLOTE JB; MCCARTHY JS; FLAX MH
    J Immunol; 1965 Jun; 94():966-75. PubMed ID: 14321441
    [No Abstract]   [Full Text] [Related]  

  • 31. STUDIES ON ADJUVANT-INDUCED POLYARTHRITIS IN RATS. 3. THE EFFECT OF "IMMUNOSUPPRESSIVE AGENTS" ON ARTHRITIS AND TUBERCULIN HYPERSENSITIVITY.
    WARD JR; CLOUD RS; KRAWITT EL; JONES RS
    Arthritis Rheum; 1964 Dec; 7():654-61. PubMed ID: 14240623
    [No Abstract]   [Full Text] [Related]  

  • 32. Significance of the quantitative relationships of antigen and adjuvant for the efficiency of the adjuvant.
    Tanaka A
    Int Arch Allergy Appl Immunol; 1969; 36():Suppl:310-27. PubMed ID: 4984657
    [No Abstract]   [Full Text] [Related]  

  • 33. Immune response to chemically modified flagellin. II. Evidence for a fundamental relationship between humoral and cell-mediated immunity.
    Parish CR
    J Exp Med; 1971 Jul; 134(1):21-47. PubMed ID: 5558070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delayed hypersensitivity skin reactions to homologous and heterologous antigens in guinea-pigs immunized with M. leprae and four selected cultivable mycobacterial strains.
    Mustafa AS; Talwar GP
    Lepr India; 1978 Oct; 50(4):509-19. PubMed ID: 374870
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunosuppressive drugs. I.
    Br Med J; 1970 Dec; 4(5736):663-5. PubMed ID: 4922755
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effect of the combined use of rifampicin and a low-molecular immunomodulator of natural origin on the primary immune response to the antigens of a tularemia vaccinal strain].
    Nikitin AV; Ivanitskaia LP; Bodunkova LE; Kovalenko LP; Fishman VM
    Antibiot Med Biotekhnol; 1985 Oct; 30(10):760-5. PubMed ID: 4091512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection against streptococcal cell wall-induced arthritis by pretreatment with the 65-kD mycobacterial heat shock protein.
    van den Broek MF; Hogervorst EJ; Van Bruggen MC; Van Eden W; van der Zee R; van den Berg WB
    J Exp Med; 1989 Aug; 170(2):449-66. PubMed ID: 2787830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunity in cutaneous leishmaniasis of the guinea-pig.
    Bryceson AD; Bray RS; Wolstencroft RA; Dumonde DC
    Clin Exp Immunol; 1970 Sep; 7(3):301-41. PubMed ID: 4249071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The adjuvant activity of mycobacterial RNA preparations and synthetic polynucleotides for induction of delayed hypersensitivity to purified protein derivative in guinea pigs.
    Casavant CH; Youmans GP
    J Immunol; 1975 Mar; 114(3):1014-22. PubMed ID: 803534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro cellular and cytokine responses to mycobacterial antigens: application to diagnosis of tuberculosis infection and assessment of response to mycobacterial vaccines.
    Lein AD; Von Reyn CF
    Am J Med Sci; 1997 Jun; 313(6):364-71. PubMed ID: 9186152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.